



A




B




**Supplementary Figure S1.** Rates of reported travel to other African countries (A) and travel outside home province in Angola (B) in Asian migrants surveyed in Angola, 2019.

Number of *P. falciparum* antigen positivity



**Supplementary Figure S2.** Empiric cumulative distribution function showing 1-proportion of with seropositivity to n *Plasmodium falciparum* antigens in Asian migrants to Angola, 2019



**Supplementary Figure S3:** Prevalence of antibody seropositivity (top panels) and strength of antibody response in those positive (bottom panels) using a panel of *Plasmodium* antigens for Asian migrants to Angola, 2019, stratifying by province. MFI-bg: median fluorescence intensity - background

**Supplementary Table S1.** Panel of antigens to assess past *Plasmodium* exposure

Abbreviation	Antigen name	Host infection stage	Full name	Organism
csp	PfCSP	Sporozoite	Circumsporozoite protein	<i>P. falciparum</i>
lsa1	LSA1	Hepatocyte	Liver-stage antigen 1	<i>P. falciparum</i>
ch150	MSP2_CH150/9	Erythrocyte	Merozoite surface protein 2	<i>P. falciparum</i> CH150 strain
Pfmsp1	PfMSP1-19	Erythrocyte	Merozoite surface protein 1, 19kD	<i>P. falciparum</i>
Pfama1	PfAMA1-N	Erythrocyte	Apical membrane antigen 1, N terminus	<i>P. falciparum</i>
hrp2	HRP2	Erythrocyte	Histidine rich protein 2	<i>P. falciparum</i>
etr5	Etramp 5 ag 1	Erythrocyte	Early transcribed membrane protein 5	<i>P. falciparum</i>
hsp40	HSP40 ag 1	Erythrocyte	Heat shock protein 40	<i>P. falciparum</i>
h103	H103/MSP11	Erythrocyte	Merozoite surface protein 11	<i>P. falciparum</i>
etr4	Etramp 4 ag 2	Erythrocyte	Early transcribed membrane protein 4	<i>P. falciparum</i>
gexP	GEXP18	Erythrocyte	Gametocyte-exported protein 18	<i>P. falciparum</i>
sea1	SEA-1	Erythrocyte	Schizont egress antigen 1	<i>P. falciparum</i>
e181	EBA181 RIII-V	Erythrocyte	Erythrocyte binding antigen 181	<i>P. falciparum</i>
rh5	Rh5.1	Erythrocyte	Reticulocyte binding homologue 5	<i>P. falciparum</i>
sbp1	SBP1	Erythrocyte	Skeleton binding protein 1	<i>P. falciparum</i>
hp2	Hyp2	Erythrocyte	Exported putative protein	<i>P. falciparum</i>
glurp0	GLURP.R0	Erythrocyte	Glutamate-rich protein R0 fragment	<i>P. falciparum</i>
glurp2	GLURP.R2	Erythrocyte	Glutamate-rich protein R2 fragment	<i>P. falciparum</i>
e140	EBA140 RIII-V	Erythrocyte	Erythrocyte binding antigen 140	<i>P. falciparum</i>
rh42	Rh4.2	Erythrocyte	Reticulocyte binding homologue 4	<i>P. falciparum</i>
Pmmsp1	PvMSP1-19	Erythrocyte	Merozoite surface protein 1, 19kD	<i>P. malariae</i>
Pvmsp1	PvMSP1-19	Erythrocyte	Merozoite surface protein 1, 19kD	<i>P. vivax</i>
chPvmsp1	chPvMSP1-19	Erythrocyte	Merozoite surface protein 1, 19kD (Chabaudi)	<i>P. vivax (P. chabaudi)</i>
dd2	MSP2_DD2	Erythrocyte	Merozoite surface protein 2	<i>P. falciparum</i> DD2 strain

**Supplementary Table S2.** Malaria knowledge and prevention practices reported by Asian migrants surveyed in Angola, 2019, stratifying by province and origin

	Luanda						Lunda Sul						Zaire					
	Chinese			Southeast Asian			Chinese			Southeast Asian			Chinese			Southeast Asian		
	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)
Knows malaria exists in Angola	137	149	92 (86-96)	114	138	83 (75-88)	87	90	97 (90-99)	193	215	90 (85-93)	91	96	95 (88-98)	27	28	96 (80-100)
Feels at risk of malaria	73	148	49 (41-58)	93	138	67 (59-75)	68	88	77 (67-85)	177	216	82 (76-87)	85	96	89 (80-94)	25	28	89 (71-97)
Knows malaria spread by mosquitoes	130	153	85 (78-90)	110	143	77 (69-83)	76	90	84 (75-91)	193	219	88 (83-92)	90	96	94 (86-97)	27	29	93 (76-99)
Heard communication about malaria in last 6 months	61	143	43 (35-51)	66	129	51 (42-60)	37	89	42 (31-53)	104	217	48 (41-55)	46	96	48 (38-58)	12	29	41 (24-61)
Source of information on malaria																		
Friends/family	33	61	54 (41-67)	34	66	52 (39-64)	21	37	57 (40-72)	66	104	63 (53-73)	33	46	72 (56-84)	9	12	75 (43-93)
TV/radio	12	61	20 (11-32)	43	66	65 (52-76)	4	37	11 (4-26)	34	104	33 (24-43)	16	46	35 (22-50)	5	12	42 (16-71)
Poster/leaflet	13	61	21 (12-34)	6	66	9 (4-19)	7	37	19 (9-36)	29	104	28 (20-38)	6	46	13 (5-27)	4	12	33 (11-65)
Employer	4	61	7 (2-17)	22	66	33 (23-46)	9	37	24 (12-42)	44	104	42 (33-52)	24	46	52 (37-67)	6	12	50 (25-75)
Other	10	61	16 (9-29)	31	66	47 (35-60)	13	37	35 (21-53)	44	104	42 (33-52)	23	46	50 (36-64)	4	12	33 (11-65)
Received information about malaria from employer	110	142	77 (70-84)	54	109	50 (40-59)	61	79	77 (66-86)	125	199	63 (56-69)	81	91	89 (80-94)	22	27	81 (61-93)
Received information about chemoprophylaxis from employer	68	140	49 (40-57)	38	102	37 (28-47)	49	80	61 (50-72)	101	194	52 (45-59)	68	90	76 (65-84)	16	26	62 (41-79)
Uses bed net	84	155	54 (46-62)	75	144	52 (44-60)	85	90	94 (87-98)	179	219	82 (76-86)	82	96	85 (76-92)	21	29	72 (53-87)
Long-lasting insecticide treated net	53	84	63 (52-73)	29	75	39 (28-51)	75	85	88 (79-94)	160	179	89 (84-93)	78	82	95 (87-98)	17	21	81 (57-94)
Source of net																		
Brought net from home	26	84	31 (22-42)	37	75	49 (38-61)	21	85	25 (16-35)	110	179	61 (54-69)	35	82	43 (32-54)	16	21	76 (52-91)
Bought net in Angola	50	84	60 (48-70)	15	75	20 (12-31)	49	85	58 (46-68)	39	179	22 (16-29)	30	82	37 (26-48)	4	21	19 (6-43)
Other	8	84	10 (4-18)	23	75	31 (21-43)	15	85	18 (11-28)	30	179	17 (12-23)	17	82	21 (13-31)	1	21	5 (0.2-26)
Slept under net last night	79	84	94 (86-98)	65	75	87 (76-93)	84	85	99 (93-100)	178	179	99 (96-100)	81	82	99 (92-100)	21	21	100 (81-100)
Travels with bed net	15	53	28 (17-43)	13	32	41 (24-59)	18	66	27 (17-40)	33	134	25 (18-33)	33	69	48 (36-60)	9	18	50 (29-71)
Uses other forms of malaria prevention																		
Insecticide spray	50	155	32 (25-40)	83	144	58 (49-66)	59	90	66 (55-75)	120	219	55 (48-61)	57	96	59 (49-69)	11	29	38 (21-58)
Fan/Air conditioning	22	155	14 (9-21)	81	144	56 (48-64)	29	90	32 (23-43)	86	219	39 (33-46)	59	96	61 (51-71)	15	29	52 (33-70)
Repellent	29	155	19 (13-26)	51	144	35 (28-44)	35	90	39 (29-50)	73	219	33 (27-40)	42	96	44 (34-54)	7	29	24 (11-44)
Coil	21	155	14 (9-20)	6	144	4 (2-9)	27	90	30 (21-41)	19	219	9 (5-13)	11	96	11 (6-20)	1	29	3 (0.2-20)
Screens	4	155	3 (0.8-7)	32	144	22 (16-30)	0	90	0 (0-5)	18	219	8 (5-13)	5	96	5 (2-12)	0	29	0 (0-15)
Indoor residual spraying	5	155	3 (1-8)	24	144	17 (11-24)	4	90	4 (1-12)	12	219	5 (3-10)	1	96	1 (0.05-6)	0	29	0 (0-15)
Electric fly swatter	3	155	2 (0.5-6)	0	144	0 (0-3)	3	90	3 (0.9-10)	0	219	0 (0-2)	2	96	2 (0.4-8)	0	29	0 (0-15)
Long-sleeved clothing/socks	1	155	0.6 (0.03-4)	1	144	0.7 (0.04-4)	1	90	1 (0.06-7)	1	219	0.5 (0.02-3)	1	96	1 (0.05-6)	0	29	0 (0-15)
Chemoprophylaxis	1	155	0.6 (0.03-4)	1	144	0.7 (0.04-4)	1	90	1 (0.06-7)	0	219	0 (0-2)	0	96	0 (0-5)	0	29	0 (0-15)
No malaria prevention reported	2	155	1 (0.2-5)	1	144	0.7 (0.04-4)	0	90	0 (0-5)	1	219	0.5 (0.02-3)	0	96	0 (0-5)	0	29	0 (0-15)

**Supplementary Table S3.** Healthcare seeking practices for febrile illness reported by Asian migrants surveyed in Angola, 2019, stratifying by province and origin

	Luanda						Lunda Sul						Zaire					
	Chinese			Southeast Asian			Chinese			Southeast Asian			Chinese			Southeast Asian		
	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)
Had fever in last 3 months	9	152	6 (3-11)	13	142	9 (5-15)	3	90	3 (0.9-10)	17	219	8 (5-12)	6	96	6 (3-14)	5	29	17 (7-36)
Self-medicated	3	9	33 (9-69)	6	13	46 (20-74)	0	3	0 (0-69)	4	17	24 (8-50)	0	6	0 (0-48)	1	5	20 (1-70)
Sought healthcare	5	9	56 (23-85)	6	13	46 (20-74)	3	3	100 (31-100)	12	17	71 (44-89)	5	6	83 (36-99)	3	5	60 (17-93)
Setting for healthcare seeking																		
Public health facility	2	5	40 (7-83)	1	6	17 (0.9-64)	1	3	33 (2-87)	4	12	33 (11-65)	2	5	40 (7-83)	0	3	0 (0-69)
Private health facility/pharmacy	3	5	60 (17-93)	3	6	50 (19-81)	2	3	67 (13-98)	7	12	58 (29-84)	3	5	60 (17-93)	3	3	100 (31-100)
Employer health facility	0	5	0 (0-54)	2	6	33 (6-76)	0	3	0 (0-69)	1	12	8 (0.4-40)	0	5	0 (0-54)	0	3	0 (0-69)
Tested for malaria	4	9	44 (15-77)	6	13	46 (20-74)	3	3	100 (31-100)	12	17	71 (44-89)	5	6	83 (36-99)	3	5	60 (17-93)
Took antimalarial drug	3	9	33 (9-69)	5	13	38 (15-68)	3	3	100 (31-100)	7	17	41 (19-67)	5	6	83 (36-99)	3	5	60 (17-93)
Following positive test	1	3	33 (2-87)	3	5	60 (17-93)	2	3	67 (13-98)	6	7	86 (42-99)	5	5	100 (46-100)	2	3	67 (13-98)
Antimalarial drug taken																		
Artemisinin-based combination therapy	0	2	0 (0-80)	3	5	60 (17-93)	0	1	0 (0-95)	2	9	22 (4-60)	0	3	0 (0-69)	1	2	50 (9-91)
Other	2	2	100 (20-100)	2	5	40 (7-83)	1	1	100 (5-100)	7	9	78 (40-96)	3	3	100 (31-100)	1	2	50 (9-91)

**Supplementary Table S4.** Prevalence of current or past malaria infection in Asian migrants surveyed in Angola, 2019, stratifying by province and origin

	Luanda						Lunda Sul						Zaire					
	Chinese			Southeast Asian			Chinese			Southeast Asian			Chinese			Southeast Asian		
	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)	n	N	% (95% CI)
<b>Current/recent infection</b>																		
RDT at time of survey																		
Any <i>Plasmodium</i> +	3	153	2 (0.5-6)	3	142	2 (0.5-7)	1	89	1 (0.06-7)	3	217	1 (0.4-4)	5	95	5 (2-12)	2	29	7 (1-24)
Pf+	1	153	0.7 (0.03-4)	2	142	1 (0.2-6)	1	89	1 (0.06-7)	3	217	1 (0.4-4)	3	95	3 (0.8-10)	1	29	3 (0.2-20)
Pv+	2	153	1 (0.2-5)	0	142	0 (0-3)	0	89	0 (0-5)	0	217	0 (0-2)	2	95	2 (0.4-8)	0	29	0 (0-15)
Pf+/Pv+	0	153	0 (0-3)	1	142	0.7 (0.04-4)	0	89	0 (0-5)	0	217	0 (0-2)	0	95	0 (0-5)	1	29	3 (0.2-20)
Negative	150	153	98 (94-99)	139	142	98 (93-99)	88	89	99 (93-100)	214	217	99 (96-100)	90	95	95 (88-98)	27	29	93 (76-99)
Ultrasensitive laboratory antigen detection																		
Any <i>Plasmodium</i> +	1	155	0.6 (0.03-4)	7	144	5 (2-10)	2	90	2 (0.4-9)	9	219	4 (2-8)	6	94	6 (3-14)	1	29	3 (0.2-20)
Pf+	0	155	0 (0-3)	5	144	3 (1-8)	2	90	2 (0.4-9)	5	219	2 (0.8-6)	6	94	6 (3-14)	1	29	3 (0.2-20)
Pv+	0	155	0 (0-3)	0	144	0 (0-3)	0	90	0 (0-5)	0	219	0 (0-2)	0	94	0 (0-5)	0	29	0 (0-15)
Pf+/Pv+	0	155	0 (0-3)	1	144	0.7 (0.04-4)	0	90	0 (0-5)	2	219	0.9 (0.2-4)	0	94	0 (0-5)	0	29	0 (0-15)
Pm+ or Po+	1	155	0.6 (0.03-4)	1	144	0.7 (0.04-4)	0	90	0 (0-5)	2	219	0.9 (0.2-4)	0	94	0 (0-5)	0	29	0 (0-15)
Negative	154	155	99 (96-100)	137	144	95 (90-98)	88	90	98 (91-100)	210	219	96 (92-98)	88	94	94 (86-97)	28	29	97 (80-100)
<b>Past infection</b>																		
Self-reported past malaria infection																		
In home country	12	155	8 (4-13)	9	144	6 (3-12)	1	90	1 (0.06-7)	14	219	6 (4-11)	3	96	3 (0.8-10)	5	29	17 (7-36)
In Angola	41	154	27 (20-34)	68	144	47 (39-56)	40	90	44 (34-55)	92	219	42 (35-49)	43	96	45 (35-55)	12	29	41 (24-61)
Laboratory antibody detection																		
Any <i>Plasmodium</i> +	82	155	53 (45-61)	51	144	35 (28-44)	55	90	61 (50-71)	141	219	64 (58-71)	54	84	64 (53-74)	13	22	59 (37-79)
Pf+	71	155	46 (38-54)	48	144	33 (26-42)	45	90	50 (40-60)	127	219	58 (51-65)	52	84	62 (51-72)	12	22	55 (33-75)
Pv+	4	155	3 (0.8-7)	0	144	0 (0-3)	3	90	3 (0.9-10)	1	219	0.5 (0.02-3)	0	84	0 (0-5)	0	22	0 (0-18)
Pf+/Pv+	7	155	5 (2-9)	2	144	1 (0.2-5)	6	90	7 (3-14)	12	219	5 (3-10)	2	84	2 (0.4-9)	1	22	5 (0.2-25)
Pm+	0	155	0 (0-3)	5	144	3 (1-8)	8	90	9 (4-17)	3	219	1 (0.4-4)	0	84	0 (0-5)	0	22	0 (0-18)
Negative	73	155	47 (39-55)	93	144	65 (56-72)	35	90	39 (29-50)	78	219	36 (29-42)	30	84	36 (26-47)	9	22	41 (21-63)

RDT: rapid diagnostic test; Pf: *P. falciparum* ; Pv: *P. vivax* ; Pm: *P. malariae* ; Po: *P. ovale*

**Supplementary Table S5.** Distribution of antigen profiles in Asian migrants in Angola, 2019

pfHRP2	pAldo	pLDH	pVLDH	Interpretation	N, frequency (N=731)	Pf RDT+	Pv RDT+	Seropositive for any Pf	Seropositive for any Pv
-	-	-	-	No malaria infection	705 (96.4%)	8/697 ( 1%)	6/697 (0.9%)	368/705 ( 52%)	33/705 ( 5%)
-	+	-	-	low level non-Pf, non-Pv	1 ( 0.1%)	0/1 ( 0%)	0/1 (0.0%)	1/1 (100%)	0/1 ( 0%)
-	-	+	-	low level non-Pf, non-Pv	3 ( 0.4%)	0/3 ( 0%)	0/3 (0.0%)	2/3 ( 67%)	0/3 ( 0%)
-	+	+	-	non-Pf, non-Pv	0 ( 0.0%)	-	-	-	-
+	+	-	-	low/recent Pf	2 ( 0.3%)	0/2 ( 0%)	0/2 (0.0%)	2/2 (100%)	0/2 ( 0%)
+	-	-	-	recent Pf	7 ( 1.0%)	0/7 ( 0%)	0/7 (0.0%)	2/7 ( 29%)	1/7 ( 14%)
+	-	+	-	low/recent Pf	10 ( 1.4%)	4/10 ( 40%)	0/10 (0.0%)	7/10 ( 70%)	2/10 ( 20%)
+	+	+	-	active Pf	0 ( 0.0%)	-	-	-	-
+	-	-	+	recent Pf, active Pv	1 ( 0.1%)	0/1 ( 0%)	0/1 (0.0%)	1/1 (100%)	1/1 (100%)
+	+	-	+	recent Pf, active Pv	0 ( 0.0%)	-	-	-	-
+	-	+	+	recent Pf, active Pv	1 ( 0.1%)	0/1 ( 0%)	0/1 (0.0%)	1/1 (100%)	1/1 (100%)
-	-	+	+	active Pv	0 ( 0.0%)	-	-	-	-
-	+	-	+	active Pv	0 ( 0.0%)	-	-	-	-
-	-	-	+	active Pv	0 ( 0.0%)	-	-	-	-
-	+	+	+	active Pv	0 ( 0.0%)	-	-	-	-
+	+	+	+	active Pf, active Pv	1 ( 0.1%)	1/1 (100%)	0/1 (0.0%)	1/1 (100%)	0/1 ( 0%)

RDT: rapid diagnostic test; Pf: *P. falciparum* ; Pv: *P. vivax*



**Supplementary Table S6.** Association between seropositivity to *Plasmodium* antigens and four key variables in Asian migrants in Angola, 2019

Antigen	Recent arrival			Active infection			Malaria at home			Ever had malaria		
	Yes	No	p-value	Yes	No	p-value	Yes	No	p-value	Yes	No	p-value
SBP1	1/29 (3%)	69/685 (10%)	0.39	5/25 (20%)	65/689 (9%)	0.16	6/43 (14%)	64/671 (10%)	0.50	<b>38/288 (13%)</b>	<b>32/425 (8%)</b>	<b>0.02</b>
PfMSP1	<b>7/29 (24%)</b>	<b>293/685 (43%)</b>	<b>0.07</b>	10/25 (40%)	290/689 (42%)	1.00	24/43 (56%)	276/671 (41%)	0.08	<b>181/288 (63%)</b>	<b>119/425 (28%)</b>	<b>0.00</b>
CH150	0/29 (0%)	1/685 (0.1%)	1.00	0/25 (0%)	1/689 (0.1%)	1.00	0/43 (0%)	1/671 (0.1%)	1.00	1/288 (0.3%)	0/425 (0%)	0.84
E181	0/29 (0%)	3/685 (0.4%)	1.00	1/25 (4%)	2/689 (0.3%)	0.21	0/43 (0%)	3/671 (0.4%)	1.00	3/288 (1%)	0/425 (0%)	0.13
LSA1	0/29 (0%)	8/685 (1%)	1.00	1/25 (4%)	7/689 (1%)	0.67	0/43 (0%)	8/671 (1%)	1.00	5/288 (2%)	3/425 (0.7%)	0.36
HP2	0/29 (0%)	0/685 (0%)	-	0/25 (0%)	0/689 (0%)	-	0/43 (0%)	0/671 (0%)	-	0/288 (0%)	0/425 (0%)	-
PfAMA1	1/29 (3%)	78/685 (11%)	0.30	6/25 (24%)	73/689 (11%)	0.08	8/43 (19%)	71/671 (11%)	0.17	<b>55/288 (19%)</b>	<b>24/425 (6%)</b>	<b>0.00</b>
HRP2	0/29 (0%)	39/685 (6%)	0.37	3/25 (12%)	36/689 (5%)	0.31	4/43 (9%)	35/671 (5%)	0.43	<b>25/288 (9%)</b>	<b>14/425 (3%)</b>	<b>0.00</b>
GLURPO	0/29 (0%)	32/685 (5%)	0.46	<b>5/25 (20%)</b>	<b>27/689 (4%)</b>	<b>0.00</b>	3/43 (7%)	29/671 (4%)	0.66	<b>26/288 (9%)</b>	<b>6/425 (1%)</b>	<b>0.00</b>
PvMSP1	0/29 (0%)	11/685 (2%)	1.00	<b>2/25 (8%)</b>	<b>9/689 (1%)</b>	<b>0.07</b>	0/43 (0%)	11/671 (2%)	0.84	4/288 (1%)	7/425 (2%)	1.00
PmMSP1	0/29 (0%)	15/685 (2%)	0.89	1/25 (4%)	14/689 (2%)	1.00	2/43 (5%)	13/671 (2%)	0.51	10/288 (3%)	5/425 (1%)	0.07
CHPvMSP1	1/29 (3%)	37/685 (5%)	0.97	<b>5/25 (20%)</b>	<b>33/689 (5%)</b>	<b>0.00</b>	2/43 (5%)	36/671 (5%)	1.00	18/288 (6%)	20/425 (5%)	0.46
ETR5	0/29 (0%)	44/685 (6%)	0.31	<b>6/25 (24%)</b>	<b>38/689 (6%)</b>	<b>0.00</b>	<b>6/43 (14%)</b>	<b>38/671 (6%)</b>	<b>0.06</b>	<b>33/288 (11%)</b>	<b>11/425 (3%)</b>	<b>0.00</b>
HSP40	0/29 (0%)	26/685 (4%)	0.57	3/25 (12%)	23/689 (3%)	0.08	4/43 (9%)	22/671 (3%)	0.10	<b>22/288 (8%)</b>	<b>4/425 (0.9%)</b>	<b>0.00</b>
CSP	0/29 (0%)	0/685 (0%)	-	0/25 (0%)	0/689 (0%)	-	0/43 (0%)	0/671 (0%)	-	0/288 (0%)	0/425 (0%)	-
H103	0/29 (0%)	10/685 (1%)	1.00	1/25 (4%)	9/689 (1%)	0.80	2/43 (5%)	8/671 (1%)	0.23	7/288 (2%)	3/425 (0.7%)	0.11
GLURP2	<b>0/29 (0%)</b>	<b>95/685 (14%)</b>	<b>0.06</b>	<b>8/25 (32%)</b>	<b>87/689 (13%)</b>	<b>0.01</b>	10/43 (23%)	85/671 (13%)	0.08	<b>70/288 (24%)</b>	<b>25/425 (6%)</b>	<b>0.00</b>
E140	1/29 (3%)	34/685 (5%)	1.00	3/25 (12%)	32/689 (5%)	0.23	5/43 (12%)	30/671 (4%)	0.08	<b>21/288 (7%)</b>	<b>14/425 (3%)</b>	<b>0.02</b>
ETR4	1/29 (3%)	28/685 (4%)	1.00	<b>5/25 (20%)</b>	<b>24/689 (3%)</b>	<b>0.00</b>	2/43 (5%)	27/671 (4%)	1.00	14/288 (5%)	15/425 (4%)	0.49
RH42	1/29 (3%)	55/685 (8%)	0.58	<b>5/25 (20%)</b>	<b>51/689 (7%)</b>	<b>0.05</b>	<b>7/43 (16%)</b>	<b>49/671 (7%)</b>	<b>0.07</b>	<b>38/288 (13%)</b>	<b>18/425 (4%)</b>	<b>0.00</b>
SEA1	1/29 (3%)	26/685 (4%)	1.00	<b>4/25 (16%)</b>	<b>23/689 (3%)</b>	<b>0.01</b>	2/43 (5%)	25/671 (4%)	1.00	12/288 (4%)	15/425 (4%)	0.81
RH5	0/29 (0%)	8/685 (1%)	1.00	1/25 (4%)	7/689 (1%)	0.67	1/43 (2%)	7/671 (1%)	0.98	5/288 (2%)	3/425 (0.7%)	0.36
GEXP	4/29 (14%)	48/685 (7%)	0.31	2/25 (8%)	50/689 (7%)	1.00	3/43 (7%)	49/671 (7%)	1.00	25/288 (9%)	27/425 (6%)	0.30
DD2	0/29 (0%)	39/685 (6%)	0.37	<b>5/25 (20%)</b>	<b>34/689 (5%)</b>	<b>0.00</b>	<b>6/43 (14%)</b>	<b>33/671 (5%)</b>	<b>0.03</b>	<b>28/288 (10%)</b>	<b>10/425 (2%)</b>	<b>0.00</b>